Custom CRISPR sgRNA Non-Viral Vectors
A non-viral vector from abm is the simplest approach to deliver sgRNAs into cells, ideal for expressing sgRNA in a transient manner to limit off-target effects. You can order custom sgRNA non-viral vectors to transfect into cells that already express the spCas9 nuclease, and thus recruit spCas9 to the target gene (check out abm’s Cas9 Expressing Stable Cell Lines). Alternatively, we can construct All-in-One non-viral vectors that express spCas9 along with the sgRNA, making it even simpler to deliver CRISPR/Cas9 technology right into the target cell. When the non-viral vector has done its work, it can be diluted out of the cell population by passaging; just monitor the GFP fluorescence signal until it is gone.
| BASIC PACKAGE 1 (CAT. NO. C316) | AAV VECTOR /VIRUS |
LENTIVECTOR /VIRUS |
NON-VIRAL VECTOR |
ADENOVIRUS |
|---|---|---|---|---|
| sgRNA for spCas9 | Available | Available | Available | Available |
| sgRNA for saCas9 | Available | – | – | – |
| All-in-One with spCas9 | – | Available | Available | – |
| All-in-One with saCas9 | Available | – | – | – |
| All-in-One with FnCas12a (FnCpf1) | – | Available | – | – |
| Browse Collection | Browse Collection | Browse Collection | Browse Collection |
Testimonial:
“Construct works beautifully, definitely will get more if needed.”
Emily Chen, UCLA, CRISPR Constructs
Additional Resources:
Service Details
| SERVICE NAME | VECTOR | QUANTITY | CAT. NO. |
|---|---|---|---|
| Custom CRISPR sgRNA Non-Viral Vector (for spCas9) – single target | pNV-sgRNA-GFP | 1.0 ug | C439 |
| Custom CRISPR sgRNA Non-Viral Vector (for spCas9) – set of three targets | pNV-sgRNA-GFP | 3 x 1.0 ug | C443 |
| Custom CRISPR All-in-One Non-Viral Vector (with spCas9) – single target | pNV-sgRNA-Cas9-2A-GFP | 1.0 ug | C440 |
| Custom CRISPR All-in-One Non-Viral Vector(with spCas9) – set of three targets | pNV-sgRNA-Cas9-2A-GFP | 3 x 1.0 ug | C444 |
Additional Info
Workflow
Additional Information & MTA
Orders of this service are subjected to the completion of a signed Material Transfer Agreement (MTA) by the purchasing individual/institution for each order. If you have any questions regarding this, please contact us at technical@abmgood.com. The end user acknowledges that the Materials provided under abm’s MTA does not grant a license for commercial use or imply any ownership rights or any intellectual property rights relating to the Materials.
Please note that if the gene to be knocked out may be essential to cell survival, it is up to the end-user to proceed with the services. abm is unable to guarantee cell survival in these cases and will only attempt to rescue the clones under these conditions. abm is not accountable for cell survival if rescuing the clones (instructions to be provided customers) is unsuccessful. If customer chooses to proceed, abm will provide a hemizygous pool as the default deliverable to compensate for any lethal effects (unless otherwise requested).
***A deposit is required to initiate all CRISPR Cell Line projects
Related Products
FAQs
Coming Soon
Citations
| 01 | Kang, Y. J. et al. “Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling.” Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371 |
| 02 | Jiang, G. et al. “Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis.” Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338 |
| 03 | Okugawa, Y. et al. “Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.” Gut (2015)doi:10.1136/gutjnl-2015-309359 |
